Darshan Patel
Schertz, TXNPI 1427513571
Payments from drug & device makers
$2,071in general payments, 2019–2025
Across 93 payments — averaging $22.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$259
- Takeda Pharmaceuticals U.S.A., Inc.$250
- Regeneron Healthcare Solutions, Inc.$242
- CSL Behring$222
- Optinose US, Inc.$148
- Amgen$147
- plus $803 from 15 others
What the payments were for
- Food & beverage$2,071100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
21
22
23
24
25
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 13 | $259 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $250 |
| Regeneron Healthcare Solutions, Inc. | 9 | $242 |
| CSL Behring | 11 | $222 |
| Optinose US, Inc. | 7 | $148 |
| Amgen | 7 | $147 |
| Kaleo, Inc. | 5 | $116 |
| Sanofi | 4 | $95 |
| AstraZeneca | 4 | $80 |
| Grifols USA, LLC | 4 | $77 |
| Genentech USA, Inc. | 3 | $73 |
| Alk-abello, Inc | 2 | $50 |
| Incyte Corporation | 2 | $48 |
| Boehringer Ingelheim | 2 | $47 |
| Biocryst US Sales Co., LLC | 2 | $42 |
| Pfizer | 2 | $40 |
| Pharming Healthcare, Inc. | 2 | $37 |
| Organon | 1 | $30 |
| Novartis | 1 | $30 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.